Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550810 | 0.88 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL550809 | 0.88 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL551665 | 0.84 | OPRL1 (0.63) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1271732 | 0.83 | OPRL1 (0.78) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL10216460 | 0.81 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1271216 | 0.74 | OPRL1 (0.76) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1271622 | 0.73 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL4546469 | 0.73 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL586455 | 0.72 | OPRL1 (0.47) | OPRL1OPRM1OPRK1 | |
| SCHEMBL550745 | 0.72 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397477-B1 | Heterocyclic-substituted piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8637502-B2 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637502-B2 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2280008-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8110602-B2 | Compounds comprising heterocyclic-substituted piperidine for treating pain | PURDUE PHARMA L.P. (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2397477-A1 | Heterocyclic-substituted piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397477-A1 | Heterocyclic-substituted piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2280008-A2 | Heterocyclic-substituted piperidines as ORL-1 ligands | Purdue Pharma L.P. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2280008-A2 | Heterocyclic-substituted piperidines as ORL-1 ligands | Purdue Pharma L.P. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2076506-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-2076506-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | OPRL1 6/4885OPRM1 17/4885OPRK1 9/4885 |
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | OPRL1 6/4885OPRM1 17/4885OPRK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.